Clinical trials: Neurocognitive Disorders, Mild
Alzheimer's Disease
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
The main purpose of this study was to assess the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.
- Trial name
- NCT05602727
- Testing
- MK-1942
- Where
- 74 sites in United States, Argentina and 9 more
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment, Alzheimer Disease
Understanding Circadian Responses to Light in Persons With Mild Cognitive Impairment
The purpose of this research study is to investigate the relationship between light, the thickness of the pigment at the back of your eye, melatonin levels, and memory.
- Trial name
- NCT05411822
- Testing
- Lighting Intervention Blue light, Lighting Intervention Green light, Dim-light control condition
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alzheimer Disease
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 weeks.
- Trial name
- REFOCUS-ALZ (NCT05026177)
- Testing
- Simufilam
- Where
- 89 sites in United States, Canada and 2 more
- Volunteers
- 1,125 people
- Sponsor
- Cassava Sciences, Inc.
Alzheimer's Disease
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
The purpose of this Phase 1/Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD and who test…
- Trial name
- NCT01561430
- Testing
- LY2886721
- Where
- 34 sites in United States, Italy and 3 more
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
This study will evaluate the effect of 150 mg MSDC-0160 taken daily for 90 days compared to the effect of placebo on changes in brain glucose utilization using FDG-PET and cognition in older persons with mild Alzheimer's disease.
- Trial name
- NCT01374438
- Testing
- MSDC-0160
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Metabolic Solutions Development Company
Mild Cognitive Impairment
ENgaging in Advance Care Planning Talks Group Visit Intervention for Cognitive Impairment
The Advance Care Planning Group Visit intervention is a new intervention that uses the strengths of group visits to promote advance care planning conversations and documentation.
- Trial name
- ENACT-aMCI (NCT03711396)
- Testing
- Advance Care Planning Group Visits
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Mild Cognitive Impairment
Plasticity Using Stimulation and Habit: A Pilot Open-label rTMS Study for MCI
The goal of this pilot study is to determine whether a high-dose form of non-invasive brain stimulation is a promising and safe treatment for Mild Cognitive Impairment (MCI).
- Trial name
- PUSH-Pilot (NCT04503096)
- Testing
- High-dose accelerated rTMS
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Medical University of South Carolina
Age-associated Cognitive Impairment, Mild Cognitive Impairment (MCI)
18-Month Study of Memory Effects of Curcumin
This project is designed to study the effects of the dietary supplement curcumin on age-related cognitive impairment. In particular, the study seeks to determine the effects of curcumin on cognitive decline and the amount of…
- Trial name
- Curcumin (NCT01383161)
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of California, Los Angeles
HIV Infections, Mild Cognitive Impairment
Feasibility of the Mindfulness-Based Stress Reduction Intervention for Black Women Living With HIV Supplement
In our Supplement Aim we will conduct a two-arm randomized pilot test of the adapted intervention compared to a usual care control group among 30 African American/Black women with HIV (15/arm) to assess the feasibility and…
- Trial name
- NCT04984681
- Testing
- Mindfulness, Usual Care
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Mild Cognitive Impairment
Lithium As a Treatment to Prevent Impairment of Cognition in Elders
Alzheimer's disease (AD) is the most common cause of dementia in adults 65 years and older. AD leads to a complete loss of memory and independent function, and presently there is no cure.
- Trial name
- LATTICE (NCT03185208)
- Testing
- Lithium Carbonate
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Ariel Gildengers, MD
Posttraumatic Stress Disorder, Depression
A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity Pilot
The goal of this pilot study is to develop and implement a larger scale, multi-site stepped collaborative care trial that targets injured patients with presentations of posttraumatic stress disorder (PTSD) and related…
- Conditions
- Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders, Suicidal Ideation
- Trial name
- TSOS6 (NCT02335125)
- Testing
- Motivational Interviewing, Cognitive Behavioral Therapy Elements, Psychotropic Drugs
- Volunteers
- 40 people
- Sponsor
- University of Washington
Mild Cognitive Impairment
Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI
To investigate whether [18F]NAV4694 positron emission tomography (PET) scan findings have the ability to distinguish subjects with mild cognitive impairment (MCI) who progress to Alzheimer's disease (AD) from those who do not.
- Trial name
- NAV4-04 (NCT01812213)
- Testing
- [18F]NAV4694
- Where
- 11 sites in United States
- Volunteers
- 76 people
- Sponsor
- Navidea Biopharmaceuticals
Mild Cognitive Impairment
Effect of Action Observation Training on Gait Variables and Global Cognitive Functions
This study will investigate the effect of Action Observation Teaining (AOT) on gait variables and global cognitive functions in older adults with mild cognitive impairment (MCI).
- Trial name
- NCT03522389
- Testing
- AOT with gait training, Gait training, Education
- Where
- Thailand
- Volunteers
- 39 people
- Sponsor
- Mahidol University
Alzheimer's Disease
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
This is a multi-center, randomized, double-blind placebo-controlled safety study conducted in 2 study cohorts. In Cohort 1, subjects with Alzheimer's disease (n=250) will receive Dimebon 20 mg or placebo TID for 26 weeks.
- Trial name
- NCT00838110
- Testing
- Dimebon
- Where
- 118 sites in United States, Canada and 1 more
- Volunteers
- 742 people
- Sponsor
- Pfizer
Alzheimer Disease
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
The primary objective of this feasibility study is to evaluate the safety of DBS-f in patients with mild Alzheimer's disease by assessing all device and/or therapy related adverse events.
- Trial name
- ADvance (NCT01608061)
- Testing
- DBS-f on, DBS-f off
- Where
- 7 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Functional Neuromodulation Ltd
Obstructive Sleep Apnea, Mild Cognitive Impairment
Mild Cognitive Impairment and Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) has been linked to increased risk for Alzheimer's disease (AD), but little prospective evidence exists on the effects of OSA treatment in preclinical AD.
- Trial name
- MEMORIES (NCT01482351)
- Testing
- CPAP adherence intervention, Attention control intervention
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- George Mason University
Mild Cognitive Impairment
Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil
Odor identification deficits, which are a result of early Alzheimer's Disease (AD) pathology in the olfactory bulb and tract as well as olfactory projection areas in the medial temporal lobe (entorhinal and piriform cortex and…
- Trial name
- NCT01845636
- Testing
- Donepezil, Atropine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- New York State Psychiatric Institute
Alzheimer Disease
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD.
- Trial name
- NCT03444870
- Testing
- Gantenerumab
- Where
- 172 sites in United States, Australia and 13 more
- Volunteers
- 1,053 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
Purpose of the study is to determine whether multiple dose administration of PF-04360365 is safe and well tolerated in patient with mild to moderate Alzheimer's disease.
- Trial name
- NCT00722046
- Testing
- PF-04360365 0.1 mg/kg, PF-04360365 0.5 mg/kg, PF-04360365 1 mg/kg
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 198 people
- Sponsor
- Pfizer
Alzheimer´s Disease
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease
The purpose of this study was to evaluate the efficacy and safety of 2 doses of Immune Globulin Intravenous (IGIV), 10% administered every 2 weeks as an intravenous (IV) infusion compared with placebo in participants with mild to…
- Trial name
- NCT00818662
- Testing
- Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg
- Where
- 41 sites in United States, Canada
- Volunteers
- 390 people
- Sponsor
- Baxalta now part of Shire